SEC 8-K and 6-K filings classified by Claude with reasoning, plus Form 4 insider transactions. Ingested from EDGAR’s filing stream in near-real time, reconciled overnight.
Showing material events only. Routine administrative filings — bylaw amendments, technical fund updates, procedural FD disclosures — are filtered out so the front page stays signal-dense.
Shareholders approved and the Board authorized a 1-for-4 reverse stock split with a corresponding reduction in authorized shares, a structural corporate action affecting the company's share structure and capitalization.
View raw filing on EDGAR →This Item 8.01 discloses the issuance and sale of approximately $832.6 million in commercial mortgage pass-through certificates (BANK5 2026-5YR22) by Wells Fargo Commercial Mortgage Securities, Inc., including publicly offered certificates ($735.8M) and privately offered certificates ($96.8M), along with detailed credit risk retention compliance under Regulation RR. While this is a material securitization transaction affecting the registrant's capital structure and investor base, it does not fit neatly into the standard 8-K event taxonomy (not an M&A activity, earnings release, or other specifically enumerated event type), making "other_material" the most appropriate classification.
View raw filing on EDGAR →Nurix disclosed updated Phase 1a/1b clinical trial data for its lead BTK degrader bexobrutideg (NX-5948) in CLL/SLL patients, presented at EHA2026, including expanded safety findings across 142 patients and an 83% objective response rate in relapsed/refractory patients, along with new Phase 1b cohort data in earlier-line treatment settings.
View raw filing on EDGAR →Summit Therapeutics withdrew a previously announced underwritten public offering effective June 10, 2026 due to market conditions. While the withdrawal itself is disclosed under Item 7.01 (Other Events), the cancellation of a planned capital raise signals material market or financial stress that would affect investor assessment of the company's liquidity and strategic position. This does not fit neatly into the dilutive_issuance category (which covers completed or announced offerings) but represents a material change in the company's financing plans.
View raw filing on EDGAR →Caribou Biosciences announced clinical trial data from two ongoing phase 1 trials: ANTLER for vispa-cel in relapsed/refractory B-cell non-Hodgkin lymphoma (82% ORR, 67% CR) and CaMMouflage for CB-011 in relapsed/refractory multiple myeloma (92% ORR, 83% ≥CR). The data, presented at the EHA 2026 Annual Meeting, demonstrates progress toward planned phase 3 trials and is material to investors assessing the company's pipeline advancement and regulatory pathway.
View raw filing on EDGAR →Philip Morris announced a regular quarterly dividend of $1.47 per share via press release on June 11, 2026, disclosed under Item 7.01 (Regulation FD Disclosure). While dividend declarations are routine corporate actions, they are material to shareholders as they affect total shareholder return and cash flow expectations. This does not fit the earnings_release category (which typically reports financial results) nor any other specific event type in the taxonomy, making other_material the most appropriate classification.
View raw filing on EDGAR →C4 Therapeutics disclosed positive Phase 1 trial data for cemsidomide in combination with dexamethasone for relapsed/refractory multiple myeloma, presented via a poster at EHA 2026 Congress and accompanied by a press release. This clinical trial progress is material to the company's pipeline prospects and would affect a reasonable investor's assessment of the registrant's development stage and competitive position.
View raw filing on EDGAR →Blue Owl Credit Income Corp. completed a $500 million debt offering on June 11, 2026, pursuant to a Purchase Agreement dated June 8, 2026, with proceeds to be used to pay down existing indebtedness. This material capital structure event was disclosed under Item 1.01 (Entry into a Material Definitive Agreement) and Item 2.03 (Creation of a Direct Financial Obligation), representing a significant refinancing or debt restructuring transaction.
View raw filing on EDGAR →This Item 2.03 disclosure describes the creation of direct financial obligations through the issuance of consolidated obligations (bonds and discount notes) by the Federal Home Loan Bank of New York. While the filing explicitly states "consolidated obligations issuance is material to the Bank," the disclosure is primarily informational and regulatory in nature—explaining the structure, joint and several liability framework, and reporting methodology for consolidated obligations rather than announcing a specific new debt issuance event. The absence of a Schedule A with specific issuance details and the emphasis on general policies and disclaimers suggest this is a routine periodic disclosure of the Bank's debt issuance program rather than a discrete material event triggering Item 2.03.
View raw filing on EDGAR →HF Foods announced adoption of a "limited duration stockholder rights plan" (a poison pill), which is a material defensive measure that affects shareholder rights and capital structure. While not fitting neatly into the standard taxonomy categories (not M&A, not exec-related, not financial restatement), adoption of a rights plan is material to investors as it signals potential takeover defense and alters voting dynamics. This is disclosed under Item 7.01 (Regulation FD Disclosure) rather than a more specific Item, supporting classification as other_material.
View raw filing on EDGAR →On June 9, 2026, the Board adopted formal committee charters for the Audit, Compensation, and Nominating and Corporate Governance committees, appointed committee members, and adopted a Code of Ethics and insider trading policy. These governance framework and compliance actions materially enhance the company's corporate governance posture.
View raw filing on EDGAR →CoreWeave announced a $3.5 billion senior notes offering intended for debt financing and general corporate purposes, including repayment of outstanding indebtedness. While this is a material capital-raising event affecting the registrant's financial structure, it does not fit cleanly into the taxonomy's more specific categories (ma_activity applies to acquisitions/dispositions, not debt issuances; dilutive_issuance applies to equity). The disclosure is material to investors as it signals significant leverage activity and refinancing strategy.
View raw filing on EDGAR →The Board authorized an additional $31.4 million share repurchase, bringing total authorized repurchases to $40 million. While share repurchase authorizations are routine capital allocation decisions, the magnitude ($31.4 million incremental authorization) and the disclosure in Item 8.01 suggest the company views this as material to investors' understanding of capital deployment strategy. However, this does not fit neatly into the more specific event categories (it is not a dilutive issuance, M&A activity, or executive compensation), so "other_material" is most appropriate.
View raw filing on EDGAR →Amendment No. 7 to the company's credit agreement added $50 million in incremental revolving loans and modified financial covenants, including replacement of a first lien leverage ratio with a total leverage ratio of 4.00:1.00. The covenant modification suggests potential financial stress or preparation for a material transaction, though no traditional M&A event is disclosed.
View raw filing on EDGAR →The board approved a $50.0 million share repurchase plan on June 2, 2026, signaling management confidence in valuation and affecting capital deployment.
View raw filing on EDGAR →The filing discloses preliminary assets under management (AUM) as of May 31, 2026 via a news release furnished under Regulation FD Disclosure. While AUM is a key operational metric for asset managers that investors monitor, this disclosure does not fit cleanly into the standard event taxonomy (not earnings, M&A, executive changes, impairments, etc.). The materiality depends on whether the AUM figures represent significant changes, but the disclosure itself—a routine monthly/quarterly AUM announcement—is a standard practice for asset managers and may be administrative rather than material in the strict sense.
View raw filing on EDGAR →Celanese issued a notice of redemption for $4.777% Senior Notes due July 19, 2026, with redemption scheduled for June 25, 2026 at par plus accrued interest. While debt redemption is a routine capital management activity, the materiality depends on the principal amount outstanding (not disclosed here). The timing—redemption just before maturity—suggests refinancing or debt paydown activity that would be material to investors assessing the company's capital structure and liquidity, but the disclosure lacks sufficient detail to classify as a more specific event type.
View raw filing on EDGAR →Chubb INA Holdings agreed to sell C$800 million in senior notes (C$400M due 2031 at 3.780% and C$400M due 2033 at 4.034%), fully guaranteed by Chubb Limited. This is a material debt issuance that raises capital and increases financial obligations, but does not fit cleanly into the M&A, dilutive equity issuance, or other specific debt-related categories (covenant breach, going concern). The disclosure is material to investors assessing the registrant's capital structure and leverage.
View raw filing on EDGAR →Amazon entered into a material definitive agreement. The specific nature of the agreement—whether involving acquisition, disposition, merger, strategic partnership, or another material contract—cannot be determined from the limited disclosure provided.
View raw filing on EDGAR →Amazon created a direct financial obligation or off-balance sheet arrangement. The specific nature of the obligation—whether debt issuance, lease arrangement, contingent liability, or other financial commitment—cannot be determined from the limited disclosure provided.
View raw filing on EDGAR →B&G Foods closed a $475 million senior notes offering on June 10, 2026, and entered into a material definitive agreement related to the offering. The company intends to use proceeds to redeem $509.3 million of existing senior notes due 2027, effectively refinancing its debt structure.
View raw filing on EDGAR →Humacyte disclosed presentation of Phase 3 clinical trial results (V012) for its ATEV product in arteriovenous access for hemodialysis patients on June 10, 2026. While this is a significant clinical milestone for a medical device company, the disclosure does not fit neatly into the earnings_release category (which typically covers financial results) nor any other specific event type. The clinical trial readout is material to investors assessing the company's pipeline and regulatory prospects, warranting classification as other_material.
View raw filing on EDGAR →Iovance received marketing authorization from Australia's Therapeutic Goods Administration for Amtagvi® in advanced melanoma on June 4, 2026. This regulatory approval is material to the company's commercial prospects and pipeline.
View raw filing on EDGAR →In connection with the business combination closing, the registrant adopted amended articles of incorporation and bylaws, including lock-up provisions affecting share transferability and governance changes, and adopted a new Code of Business Conduct and Ethics.
View raw filing on EDGAR →Prologis priced a ¥44.7 billion (~$280.6 million) offering of senior unsecured notes in three tranches (2030, 2035, and 2041 maturities) on June 4, 2026, with closing expected June 11, 2026. The proceeds will be used for debt repayment and general corporate purposes.
View raw filing on EDGAR →This disclosure furnishes preliminary assets under management (AUM) as of May 31, 2026 via a news release under Regulation FD. While AUM is a key operational metric for asset managers and would be material to investors assessing the registrant's business performance and client flows, it does not fit neatly into the more specific event categories (it is not an earnings release, M&A activity, executive change, or other defined event type). The disclosure is material but best classified as other_material.
View raw filing on EDGAR →The filing discloses reaffirmation of full-year 2026 earnings guidance ($19.85 per diluted share including unfavorable items; $26.75 adjusted) and benefit expense ratio guidance (90.2% ± 50 bps) during investor meetings. While this is forward-looking guidance rather than an earnings release (which typically reports historical results), the reaffirmation of specific quantitative earnings and operational metrics would materially affect a reasonable investor's assessment of the company's expected financial performance. This does not fit cleanly into earnings_release (no historical results reported) but is material guidance disclosure that warrants classification as other_material.
View raw filing on EDGAR →Cullinan Therapeutics disclosed updated Phase 1 clinical trial data for CLN-978 in rheumatoid arthritis and systemic lupus erythematosus, along with initial Phase 1b/2a data for velinotamig in SLE, demonstrating positive efficacy and safety signals including clinical remission in RA patients and rapid improvements in SLE biomarkers. This clinical progress represents material advancement of the company's pipeline that would affect a reasonable investor's assessment of the company's valuation and strategic direction.
View raw filing on EDGAR →Fold Holdings disclosed a material transaction involving the monetization of $45 million in bitcoin and elimination of $20 million in debt, which would affect a reasonable investor's assessment of the company's liquidity, asset position, and leverage. While this does not fit neatly into the standard M&A, impairment, or covenant categories, the scale and nature of the transaction (significant asset liquidation and debt reduction) constitute a material event requiring disclosure under Regulation FD.
View raw filing on EDGAR →The disclosure announces the expiration and final results of debt exchange offers and consent solicitations by Qwest/Lumen to exchange approximately $2 billion in outstanding notes (2056 and 2057 notes) for new notes with shorter maturities (2051 and 2052). While this involves debt restructuring, it does not fit cleanly into the "ma_activity" category (which typically covers acquisitions, dispositions, mergers, or changes of control) nor does it constitute a covenant breach, restatement, or other more specific event type. The exchange offer completion is material to investors as it affects the company's debt structure and maturity profile, but the specific event—completion of a debt exchange offer—lacks a dedicated taxonomy category.
View raw filing on EDGAR →National Fuel Gas Company disclosed the offering and sale of $1.5 billion in aggregate principal amount of senior notes across three tranches (2029, 2031, and 2036 maturities) with rates ranging from 4.75% to 5.50%. While this is a material debt issuance that would affect a reasonable investor's assessment of the company's capital structure and financial obligations, it does not fit cleanly into the "dilutive_issuance" category (which focuses on equity securities) or "ma_activity" (which addresses acquisitions, dispositions, or changes of control). The disclosure is material but represents a debt financing event that falls outside the more specific taxonomy categories.
View raw filing on EDGAR →The Board approved a 2026 Common Share Repurchase Program authorizing up to 500,000 shares with a maximum aggregate purchase price of $15,000,000. While share repurchase programs are routine capital allocation decisions, this authorization is material to investors as it signals management's confidence in valuation, affects share count and EPS calculations, and represents a significant deployment of capital. The disclosure does not fit neatly into the more specific event categories (not an earnings release, executive change, M&A, impairment, or litigation), making "other_material" the appropriate classification.
View raw filing on EDGAR →Dell Technologies entered into a $6 billion senior unsecured revolving credit facility on June 10, 2026, replacing an existing credit agreement. This refinancing arrangement materially affects the company's liquidity and capital structure, though it does not constitute an M&A transaction or change of control.
View raw filing on EDGAR →Northern States Power Company-Wisconsin entered into a Bond Purchase Agreement for $250 million in First Mortgage Bonds due 2041, representing a material debt issuance that affects the company's capital structure and financial obligations.
View raw filing on EDGAR →The company entered into a material definitive agreement disclosed under Item 1.01, though the specific nature of the agreement (whether M&A activity, significant contract, or other transaction) cannot be determined without the full filing text.
View raw filing on EDGAR →Fifth Third Bancorp completed a material debt restructuring involving exchange offers and consent solicitations on June 10, 2026, exchanging approximately $1.27 billion in Comerica-issued notes (assumed by FTFC) for new Fifth Third Bancorp notes while eliminating significant covenants and events of default from the original indentures. This is a material capital structure event affecting the company's debt obligations and financial flexibility, but does not fit neatly into the more specific categories (not an M&A activity, impairment, or covenant breach—rather a proactive refinancing and covenant elimination). The elimination of restrictive covenants and events of default is particularly significant to investors assessing financial risk.
View raw filing on EDGAR →WhiteHawk Minerals Corp. completed its initial public offering on June 10, 2026, raising approximately $200.2 million in gross proceeds from the sale of 7.7 million shares at $26.00 per share, with listing on the NYSE under ticker 'WHK.' This transformative capital-raising event materially affects the company's capitalization and public market status.
View raw filing on EDGAR →WhiteHawk Minerals redeemed all outstanding Series D Preferred Stock for approximately $39.9 million on June 10, 2026. This significant capital event materially affects the rights and economic interests of preferred shareholders and represents a substantial use of capital in connection with the company's public offering.
View raw filing on EDGAR →WhiteHawk Minerals created direct financial obligations through an amendment to a revolving credit facility and a change in issuer under a note purchase agreement in connection with its internalization and public offering. The specific nature and materiality of these obligations depend on whether they involve debt covenant modifications, equity dilution, or other triggering events.
View raw filing on EDGAR →WhiteHawk Minerals amended its Certificate of Incorporation and Bylaws effective June 10, 2026 in connection with its public offering. The disclosure provides limited substantive detail about the specific provisions altered, though the amendments are material to the company's governance structure in connection with going public.
View raw filing on EDGAR →American Eagle entered into Amendment No. 2 to its $700 million ABL Credit Agreement, extending the maturity date from June 2027 to June 2031 and restructuring interest rate terms. This material amendment to a significant credit facility affects the company's debt structure and financial flexibility.
View raw filing on EDGAR →The company announced completion of enrollment in the Phase 2 TX45 APEX clinical trial for a therapeutic candidate targeting pulmonary hypertension with heart failure with preserved ejection fraction (PH-HFpEF). This represents a significant clinical development milestone for the company's pipeline.
View raw filing on EDGAR →Rafael Holdings announced completion of the final 96-week study visit in its pivotal Phase 3 TransportNPC™ study for Trappsol® Cyclo™ in Niemann-Pick Disease Type C, with topline data expected in H2 2026. This represents a material clinical milestone for the company's lead therapeutic candidate.
View raw filing on EDGAR →This disclosure announces the Company's intent to enter into Non-Redemption Agreements with unaffiliated shareholders in connection with an extraordinary general meeting to approve an extension of time to complete an initial business combination. The agreements would incentivize shareholders not to redeem their Class A shares by offering Class B shares from the Sponsor at a negotiated ratio. While this involves shareholder voting mechanics and potential dilutive equity issuances, the core event is the announcement of a material transaction structure (non-redemption agreements with equity consideration) that affects the capital structure and shareholder base, which does not fit cleanly into the more specific categories but is clearly material to investors assessing the Company's path to completing a business combination.
View raw filing on EDGAR →Mountain Lake Acquisition Corp. announced a postponement of its extraordinary general meeting from an unspecified earlier date to June 16, 2026, to allow additional time to complete its business combination with Avalanche Treasury Corporation. While the postponement itself is administrative, the underlying business combination approval and the extension of the deadline to consummate the transaction (from June 16 to September 16, 2026) are material to shareholders' assessment of the SPAC's ability to close its transaction. This does not fit neatly into ma_activity (which typically covers entry, completion, or termination of M&A) since the business combination was already approved on June 4, 2026, and this disclosure concerns only a procedural postponement and timeline extension rather than a new M&A event.
View raw filing on EDGAR →This disclosure reports the consummation of Keystone Acquisition Corp.'s IPO on June 4, 2026, generating $287.5 million in gross proceeds from 28.75 million units, plus a concurrent private placement of 8.47 million warrants for $8.47 million. While the IPO itself is a material capital-raising event, the filing is structured as Item 8.01 (Other Events) rather than Item 2.01 (Completion of Acquisition or Disposition) or a dedicated IPO item, and the disclosure focuses on confirming previously reported facts rather than announcing new material developments. The event is material to investors but does not fit cleanly into the earnings_release, ma_activity, or dilutive_issuance categories as typically understood in the taxonomy.
View raw filing on EDGAR →The disclosure announces a postponement of the extraordinary general meeting scheduled to vote on a proposed business combination between M3-Brigade Acquisition V Corp. and ReserveOne, Inc., moving the vote from June 15 to June 18, 2026, and extending the shareholder redemption deadline. While this is a material event affecting shareholders' ability to vote on and redeem shares in connection with a significant M&A transaction, it is procedural in nature (a meeting postponement) rather than a substantive change to the business combination itself. The event does not fit neatly into the ma_activity category (which covers entry, completion, or termination of M&A) or shareholder_vote_results (which covers actual vote outcomes), making other_material the most appropriate classification.
View raw filing on EDGAR →The filing discloses an extension of byNordic's business combination deadline from June 12, 2026 to July 12, 2026, funded by a $17,470 deposit into the Trust Account. This is a material event for a SPAC as it directly affects the timeline for completing the initial business combination and the company's continued existence. While not a traditional M&A completion, the extension is a critical milestone event that would affect investor assessment of the registrant's prospects and timeline.
View raw filing on EDGAR →The disclosure announces commencement of field operations for a planned sidetrack phase of the Megiddo-Jezreel #2 well in Israel, including re-entry, drilling out a temporary plug, wellbore conditioning, and horizontal sidetrack drilling. While this represents a material operational milestone for an exploration company with active petroleum operations, it does not fit neatly into the more specific event categories (not an earnings release, executive change, M&A activity, impairment, or other defined event types). The operational progress on a material exploration project would affect a reasonable investor's assessment of the company's execution and prospects.
View raw filing on EDGAR →CervoMed disclosed entry into a Purchase Agreement and provided business updates via press release on June 10, 2026, including Strategic Pipeline Priorities. The specific terms and financial impact of the Purchase Agreement are not detailed in the filing excerpt, preventing confident classification as a more specific event type such as M&A activity.
View raw filing on EDGAR →